Emalex Biosciences raises $250 million to treat stuttering and Tourettes

Emalex Biosciences announced it closed a $250 million Series D funding round this week.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news